EQT Life Sciences

EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF130 Million. Noema Pharma is a clinical-stage biotech company developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The investment builds on EQT Life Sciences’ previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo , MD. Learn more about the investment here: https://lnkd.in/dH6qnE9s

C-sections are the most common major surgical procedure globally, with over 30 million performed each year. Innovation within this area of maternal health has the potential to improve the quality of care and reduce healthcare costs for millions. Against this backdrop, EQT Life Sciences has lead NUA SURGICAL's Series A funding round. Nua Surgical's surgical retractor, which is specifically designed for the unique dynamics of C-section surgery, aims to reduce the risk factors that lead to surgical complications, benefiting the patient, the clinician, and the healthcare system. Learn more about the investment here: https://lnkd.in/emCZ5G-3

Exciting news from our EQT Life Sciences portfolio company Tubulis GmbH, congratulations on this great achievement.

Congrats to the Tubulis GmbH Team for winning two awards in one night! Well deserved. It is also the second time in a row an EQT Life Sciences Life Sciences portfolio company is named Biotech Company of the Year after Amolyt Pharma Pharma took the price home last year. A testament to these outstanding companies, their teams, and top notch science.

EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in atbtherapeutics. The €54 Million Series A financing was co-led by EQT Life Sciences and MRL Ventures Fund (MRLV, a corporate venture arm of Merck & Co., Inc., Rahway, N.J., USA) alongside contributions from V-Bio Ventures, VIVES Partners, the Belgian sovereign fund SFPIM-International, Wallonie Entreprendre, Sambrinvest, and existing investors. ATB Therapeutics is dedicated to pioneering first-in-class biologics that incorporate novel cell-killing mechanisms, including enzymatic functionalities, within targeted antibodies. The Company is also welcoming seasoned biotech investors John de Koning, Partner at EQT Group, and Karin Kleinhans, Partner at MRLV, to its Board of Directors https://lnkd.in/ehetdfvG

Exciting news from the EQT Life Sciences Dementia Fund, where AviadoBio, one of our portfolio companies, just entered into an Option and License Agreement with Astellas Pharma. Under this agreement, AviadoBio granted Astellas Pharma an exclusive option to license their progranulin gene therapy program upon the readout of an ongoing phase 1/2 clinical study in frontotemporal dementia. By exercising their option to license , Astellas Pharma will trigger payment of a substantial license fee and potential development and commercialisation milestone payments to AviadoBio. As part of this deal, Astellas Pharma also made an equity investment in the Series B round of AviadoBio, which closed simultaneously today. https://lnkd.in/eaJbhb4c

Congratulations team EQT Life Sciences with this deal.

EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PANTERA, which aims to accelerate global actinium-225 production. The oversubscribed EUR 93 million equity round marks the largest Series A funding round ever in Life Science in Belgium, a testament to the company's vision and execution plan. EQT Life Sciences is joined in this investment by Kurma Partners, Eurazeo, Paladin Asset Management, Korys, and PMV as followers. With additional equity and debt funding, the total amount raised is EUR 134 million. PanTera is now fully funded to complete its game-changing venture, enabling the large-scale, dependable supply of Actinium-225 in time for the anticipated commercialization of Actinium-based radiopharmaceuticals. EQT Life Sciences wants to express its gratitude to the existing shareholders, SCK CEN, IBA, and SFPIM, as well as to its legal advisor, A&O Shearman. https://lnkd.in/egcv-VYm #actinium #radiopharmaceuticals #TAT #isotopeha #radioisotope #nuclear #medicine

EQT Life Sciences is delighted to announce that it has invested in Asceneuron SA’s oversubscribed Series C and Prof. Philip Scheltens will join the board of directors. Asceneuron SA – which is developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease – will use the funds to progress its lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease

EQT Life Sciences portfolio company Tubulis GmbH Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer. An important step forwards for patients as OC is the leading cause of death among women diagnosed with gynaecological cancers, and nearly all patients who don't respond to platinum therapies will sooner or later develop resistance. Once resistant, outcomes are poor with a median survival of less than 16 months, leaving patients in desperate need of new treatment options. Read the full press release here: https://bit.ly/3RLXGNE